Shingles jab helps give GlaxoSmithKline a boost with a record £731m in sales  

0

Shingles jab helps give GlaxoSmithKline a boost with a record £731m in sales

  • The pharma giant reported revenue of £6.9bn in the three month period, up 13pc year-on-year, as sales of shingrix more than doubled to a record £731m 
  • As a result, GSK predicted group sales would grow between 6pc and 8pc this year, up from previous forecast
  • Meanwhile profits were expected to rise 13pc to 15pc, compared with 12pc to 14pc previously

GSK chief executive Emma Walmsley hailed the ‘excellent’ performance

Drugs giant GlaxoSmithKline raised profit forecasts after soaring sales of its shingles vaccine boosted performance in the second quarter. 

The pharma giant reported revenue of £6.9bn in the three month period, up 13pc year-on-year, as sales of shingrix more than doubled to a record £731m. 

As a result, GSK predicted group sales would grow between 6pc and 8pc this year, up from previous forecasts, while profits were expected to rise 13pc to 15pc, compared with 12pc to 14pc previously. 

The results were the first after the demerger of its consumer healthcare arm Haleon, which listed in London this month. 

Chief executive Emma Walmsley hailed the ‘excellent’ performance, adding that Glaxo was continuing to ‘strengthen’ its pipeline of new drugs. 

But the shares rose only 0.1pc, or 0.8p, to 1755.8p after it forecast lower growth in the second half due to more research and development spending.

FOLLOW US ON GOOGLE NEWS

 

Read original article here

Denial of responsibility! Vigour Times is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment
Enable Notifications    OK No thanks